Huons Co., Ltd. Initiates Class II Recall for 7.1 Million Sodium Chloride Injection Ampules Over Sterility Concerns
Huons Co., Ltd. has initiated a Class II recall for 7,120,750 ampules of 0.9% Sodium Chloride Injection, USP, distributed nationwide in the USA. The recall, D-0531-2026, stems from a critical lack of assurance of sterility. This event necessitates immediate action from procurement and regulatory teams to mitigate supply chain disruptions and reassess supplier compliance.
FDA Class II Recall: Huons Co., Ltd.'s Sodium Chloride Injection Lacks Sterility Assurance
Huons Co., Ltd., based in Jecheon, Korea, has initiated a voluntary Class II recall, identified as D-0531-2026, for a substantial quantity of its 0.9% Sodium Chloride Injection, USP, 10 mL Ampules. This critical action, initiated on April 2, 2026, and reported to the FDA on April 22, 2026, affects 7,120,750 ampules distributed nationwide across the USA. The primary reason for this recall is a profound 'lack of assurance of sterility,' a severe deficiency for any injectable product. This particular product, a single-dose, preservative-free solution, is manufactured by Huons Co., Ltd. for Spectra Medical Devices, LLC, located in Wilmington, MA. The affected lots encompass all products within their expiry period, indicating a potentially widespread manufacturing control issue rather than an isolated batch problem. For procurement directors, this signifies an immediate need to verify inventory and sourcing channels, as a Class II recall implies a situation where the use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. Regulatory affairs heads must understand the implications of such a broad sterility failure on their own supplier qualification processes and product safety assessments.
Supply Chain Impact: Critical Injectable Shortages and Manufacturer Scrutiny
The recall of over 7 million ampules of 0.9% Sodium Chloride Injection, USP, poses a significant risk to the USA's healthcare supply chain. Sodium Chloride Injection is a foundational medical product, essential for intravenous fluid replacement, drug dilution, and wound irrigation across hospitals, clinics, and other medical facilities. The sheer volume of recalled units, coupled with the nationwide distribution pattern, suggests potential for widespread shortages if alternative, qualified suppliers are not readily available. Supply chain VPs must urgently identify if their downstream partners or internal operations rely on this specific product (NDC 65282-1510-1 or 65282-1505-1) and initiate contingency plans. The fact that Huons Co., Ltd. manufactures this product for Spectra Medical Devices, LLC, adds a layer of complexity, requiring both firms to address the root cause and communicate transparently with their respective customers. Business development executives should note the immediate market opportunity for compliant manufacturers of sterile injectables, particularly those with robust quality systems capable of meeting stringent FDA sterility requirements. This event underscores the vulnerability of relying on single-source or inadequately vetted contract manufacturing organizations (CMOs) for critical medical supplies.
Broader Industry Trends: Persistent Sterility Assurance Challenges Across Pharma
This recall by Huons Co., Ltd. is not an isolated incident but rather indicative of a concerning trend of sterility assurance failures within the pharmaceutical industry. Recent parallel events highlight this systemic challenge, impacting multiple companies and critical injectable products. For instance, Spectra Medical Devices, LLC, the company for whom Huons Co., Ltd. manufactured the recalled Sodium Chloride, also faced a high-severity FDA Class II recall for its Lidocaine HCl Injection due to sterility assurance deficiencies, as reported on June 10, 2026. Similarly, Essential Wellness Pharma initiated a Class II recall for its Progesterone Injection on June 15, 2026, also citing sterility assurance failures. These recurring issues across different manufacturers and product types — from basic saline solutions to specialized injectables like Lidocaine HCl and Progesterone — signal a need for heightened vigilance. Regulatory affairs heads must critically review their internal and supplier-side sterility testing protocols, environmental monitoring programs, and aseptic processing controls. Procurement directors should prioritize diversification of their sterile injectable supply base, seeking suppliers with demonstrable track records of robust quality and compliance to mitigate risks associated with widespread manufacturing deficiencies.
Mitigating Risk: Regulatory Scrutiny and Business Continuity Planning
The ongoing status of this Class II recall for 0.9% Sodium Chloride Injection means that the FDA's oversight and potential enforcement actions against Huons Co., Ltd. are still developing. While the recall was firm-initiated and voluntary, the FDA's classification of it as Class II underscores the potential for adverse health consequences. For companies sourcing from Huons Co., Ltd. or other manufacturers in Korea, this event signals increased regulatory scrutiny on their manufacturing practices, particularly for sterile products. Procurement teams should immediately engage with their suppliers to understand their exposure to Huons Co., Ltd.'s manufacturing processes or similar sterility risks. Regulatory affairs professionals should prepare for potential audits or requests for additional data regarding their supplier qualification and ongoing monitoring programs. Business development executives should evaluate market opportunities arising from potential supply gaps and consider partnerships with manufacturers demonstrating superior quality control. Proactive risk mitigation, including identifying and qualifying alternative suppliers and strengthening internal quality oversight, is paramount to ensure business continuity and patient safety in the face of such critical regulatory actions.